Virtual screening, molecular docking studies and DFT calculations of FDA approved compounds similar to the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was confirmed as the causative virus of COVID-19 disease, which is currently a worldwide pandemic. Efavirenz, a non-nucleoside reverse transcriptase inhibitor (NNRTI), is one of the most potent chemical compounds proposed to treat COVID-19...
Main Authors: | Maryam A. Jordaan, Oluwakemi Ebenezer, Nkululeko Damoyi, Michael Shapi |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-08-01
|
Series: | Heliyon |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844020314869 |
Similar Items
-
Efavirenz: History, Development and Future
by: Bárbara Costa, et al.
Published: (2022-12-01) -
Comparison of Efavirenz and Doravirine Developmental Toxicity in an Embryo Animal Model
by: Daniela Zizioli, et al.
Published: (2023-07-01) -
Global Conformational Dynamics of HIV-1 Reverse Transcriptase Bound to Non-Nucleoside Inhibitors
by: Peter V. Coveney, et al.
Published: (2012-07-01) -
DFT and molecular docking investigations of oxicam derivatives
by: Y.Shyma Mary, et al.
Published: (2019-07-01) -
Development of reverse phase high-performance liquid chromatographic method for the estimation of HIV non-nucleoside reverse transcriptase inhibitor drug efavirenz in the rat brain
by: Smita Prakash Kakad, et al.
Published: (2021-01-01)